News

  • Photonz successfully transfers process to industrial scale

    Posted on Nov. 21 2011

    Photonz Corporation has achieved a major milestone on the path to commercially manufacturing, by fermentation, the high-value omega-3 fatty acid, EPA...
  • Photonz signs with Novasep

    Posted on Sep. 21 2011

    Biotech company Photonz Corporation has entered into a development agreement with Novasep, a world-class provider of purification technology...
  • Photonz Corporation signs with Separex

    Posted on Apr. 6, 2011

    Under the agreement Separex, under a license of Stanipharm, will develop a manufacturing process, scalable to industrial volumes, to concentrate the Omega-3 fatty acid, eicosapentaenoic acid (EPA), which Photonz extracts from fermented microalgal biomass...
 

The Product

Photonz fermentation product PNZ0901, is a drug substance comprising high purity eicosapentaenoic acid (EPA).

This product is produced using Photonz' proprietary algal fermentation technology which overcomes a number of obstacles previously encountered in continuous fermentation of microalgae.

Compared with existing methods of production the Photonz method has several significant advantages. It is; sustainable; secure; traceable; consistent; scaleable and animal-free.

Photonz owns or controls seven patent families covering fermentation and purification of microalgal EPA.